M. Schechter

K. Ensrud, J. Shepherd, A. Schwartz, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings

M. Egger, E. Delaporte, F. Dabis, 2012, BMC Infectious Diseases.

Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis

E. Negredo, P. Vernazza, P. Cahn, 2011, PloS one.

Discordant immunological and virological responses to antiretroviral therapy.

M. Schechter, S. Tuboi, 2006, The Journal of antimicrobial chemotherapy.

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.

N. Wolfe, J. Shiver, W. Straus, 2010, Vaccine.

Antiretroviral therapy in resource‐limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub‐Saharan Africa, Asia and Latin America

K. Anastos, L. Myer, M. Egger, 2008, Tropical medicine & international health : TM & IH.

Antiretroviral therapy in resource-poor settings: scaling up inequalities?

M. Egger, P. Miotti, M. Schechter, 1969, International journal of epidemiology.

J. Nachega, J. Rockstroh, C. Beyrer, 2012, Journal of the International Association of Physicians in AIDS Care.

HIV Provider–Patient Communication Regarding Cardiovascular Risk

J. Nachega, J. Rockstroh, J. Zuniga, 2014, Journal of the International Association of Providers of AIDS Care.

Gender and survival after AIDS in Rio de Janeiro, Brazil.

L. Moulton, L. Harrison, M. Schechter, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Mortality Associated With Discordant Responses to Antiretroviral Therapy in Resource-Constrained Settings

C. Yiannoutsos, R. Stone, M. Egger, 2010, Journal of acquired immune deficiency syndromes.

Prioritization of antiretroviral therapy in patients with high CD4 counts, and retention in care: lessons from the START and Temprano trials

M. Schechter, 2018, Journal of the International AIDS Society.

Comparison of the prevalence of antibodies to human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) in Brazil and Colorado.

R. Schooley, L. Fitzpatrick, R. Badaró, 1998, The Journal of infectious diseases.

Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.

Megha L Mehrotra, D. Glidden, S. Buchbinder, 2014, The Lancet. Infectious diseases.

Limited Penetration of Lopinavir and Ritonavir in the Genital Tract of Men Infected with HIV-1 in Brazil

M. Schechter, G. Suarez-Kurtz, J. Cerbino-Neto, 2006, Therapeutic drug monitoring.

Myelopathy Among Brazilians Coinfected with Human T-cell Lymphotropic Virus Type I and HIV

T. Quinn, J. McArthur, D. M. Taveira, 1997, Neurology.

HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico

N. Volkow, K. Tashima, D. Podzamczer, 2016, Journal of the International AIDS Society.

Therapy of early HIV infection: time for the pendulum to swing back?

L. Harrison, M. Schechter, 1999, AIDS clinical care.

Late diagnosis of HIV infection in Brazil despite over 15 years of free and universal access to treatment.

A. Pacheco, M. Schechter, 2012, AIDS research and human retroviruses.

Raltegravir with optimized background therapy for resistant HIV-1 infection.

D. Hazuda, B. Clotet, C. Katlama, 2008, The New England journal of medicine.

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.

B. Clotet, J. Gatell, D. Cooper, 2013, The Lancet. Infectious diseases.

Continuous Increase of Cardiovascular Diseases, Diabetes, and Non-HIV Related Cancers as Causes of Death in HIV-Infected Individuals in Brazil: An Analysis of Nationwide Data

L. Harrison, A. Pacheco, M. Schechter, 2014, PloS one.

Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression

J. Miro, D. Cooper, J. Weber, 2014, AIDS.

Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection

P. Kaleebu, J. Miro, D. Cooper, 2016, Journal of acquired immune deficiency syndromes.

Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection

P. Kaleebu, D. Cooper, J. Weber, 2014, Journal of the International AIDS Society.

Enhanced Normalization of CD 4 / CD 8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection

P. Kaleebu, J. Miro, D. Cooper, 2022 .

Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities

J. Nachega, J. Mellors, L. Mofenson, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence of antibodies to 72-kilodalton glycoprotein (GP72) in patients with Chagas' disease and further evidence of zymodeme-associated expression of GP72 carbohydrate epitopes

M. Miles, M. Schechter, D. Snary, 1986, Infection and immunity.

Predicting CD4 counts in HIV-infected Brazilian individuals: a model based on the World Health Organization staging system.

M. Schechter, M. A. Perez, R. Zajdenverg, 1994, Journal of Acquired Immune Deficiency Syndromes.

Association between male circumcision and prevalent HIV infections in Rio de Janeiro, Brazil.

M. Schechter, A. Périssé, W. Blattner, 2009, Journal of acquired immune deficiency syndromes.

Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil

L. Harrison, M. Schechter, G. Santoro-Lopes, 2001, AIDS.

The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.

R. Grant, K. Mayer, M. Schechter, 2016, Journal of acquired immune deficiency syndromes.

The Safety of Tenofovir–Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B

R. Grant, K. Mayer, M. Schechter, 2016, Journal of acquired immune deficiency syndromes.

Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil. Impact on markers of HIV disease progression.

T. Quinn, L. Moulton, L. Harrison, 1994, JAMA.

Willingness to Participate in HIV Vaccine Trials Among Men Who Have Sex With Men in Rio de Janeiro, Brazil

L. Harrison, M. Schechter, A. Périssé, 2000, Journal of acquired immune deficiency syndromes.

Behavioral Impact, Acceptability, and HIV Incidence Among Homosexual Men With Access to Postexposure Chemoprophylaxis for HIV

L. Moulton, L. Harrison, M. Schechter, 2004, Journal of acquired immune deficiency syndromes.

Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs

V. Soriano, F. Altice, M. Schechter, 2010, The Lancet.

How the Pandemic Shapes the Public Health Response – the Case of HIV/AIDS in Brazil

M. Schechter, M. Vitoria, J. Galvao, 2008 .

HIV/AIDS research in Brazil: the missing piece?

M. Schechter, E. Kallas, 2006 .

Incident HIV infection in a high-risk, homosexual, male cohort in Rio de Janeiro, Brazil.

L. Moulton, L. Harrison, M. Schechter, 1999, Journal of acquired immune deficiency syndromes.

Prevalence and risk factors associated with syphilis in a cohort of HIV positive individuals in Brazil

M. Schechter, E. Sprinz, L. W. Lunardi, 2012, AIDS care.

Genetic Variation and Susceptibilities to Protease Inhibitors among Subtype B and F Isolates in Brazil

D. Pieniążek, A. Tanuri, A. Vicente, 1999, Antimicrobial Agents and Chemotherapy.

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

Michael S Saag, Mauro Schechter, Paul A Volberding, 2002, JAMA.

Increase in Non-AIDS Related Conditions as Causes of Death among HIV-Infected Individuals in the HAART Era in Brazil

L. Harrison, A. Pacheco, M. Schechter, 2008, PloS one.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

H. Lane, D. Cooper, A. Phillips, 2015, The New England journal of medicine.

Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration.

N. Low, M. Egger, F. Dabis, 2008, Journal of women's health.

Manual de HIV/AIDS

M. Schechter, M. Rachid, 2008 .

Risk-based assessment does not distinguish between recent and chronic HIV-1 infection in Rio de Janeiro, Brazil.

M. Schechter, S. Tuboi, P. Barroso, 2009, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

A Brazilian perspective

M. Schechter, 1997, The Lancet.

Syphilis Predicts HIV Incidence Among Men and Transgender Women Who Have Sex With Men in a Preexposure Prophylaxis Trial

D. Glidden, S. Buchbinder, R. Grant, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries

J. Sterne, M. Egger, F. Dabis, 2006, The Lancet.

High Prevalence of Sexually Transmitted Diseases in Young Women Seeking HIV Testing in Rio de Janeiro, Brazil

R. Ness, R. Cook, L. Harrison, 2004, Sexually transmitted diseases.

Detection of genetically diverse human immunodeficiency virus type 1 group M and O isolates by PCR

A. Tanuri, S. Kwok, N. Shaffer, 1997, Journal of clinical microbiology.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

David V Glidden, Kenneth H Mayer, Mauro Schechter, 2010, The New England journal of medicine.

Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men

Peter L. Anderson, Javier R. Lama, Kenneth H. Mayer, 2012, Science Translational Medicine.

Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents.

J. Kublin, D. Mehrotra, J. Shiver, 2005, The Journal of infectious diseases.

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

D. Hazuda, B. Clotet, C. Katlama, 2008, The New England journal of medicine.

UvA-DARE ( Digital Academic Repository ) Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1

B. Gazzard, C. Katlama, P. Reiss, 2017 .

Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1

B. Gazzard, F. van Leth, C. Katlama, 2004, PLoS medicine.

UvA-DARE ( Digital Academic Repository ) Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV

B. Gazzard, C. Katlama, P. Reiss, 2004 .

Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities

J. Nachega, E. Mills, M. Schechter, 2010, Current opinion in HIV and AIDS.

Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine

A. Vibhagool, P. Cahn, J. Jordan, 2004, Current medical research and opinion.

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis

D. Glidden, R. Grant, L. Bekker, 2014, AIDS.

Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies

Rachael Hughes, Matthias Egger, Mauro Schechter, 2008, AIDS.

Antiviral efficacy of entecavir in nucleos(t)ide‐naïve patients of Black/African descent with chronic hepatitis B

M. Schechter, R. Paraná, C. Llamoso, 2014, Journal of viral hepatitis.

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.

D. Glidden, S. Buchbinder, R. Grant, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Treatment for adult HIV infection.

Martin S. Hirsch, Mauro Schechter, Michael S. Saag, 2004 .

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

S. Hammer, D. Katzenstein, R. Schooley, 2004, JAMA.

Rates and Reasons for Early Change of First HAART in HIV-1-Infected Patients in 7 Sites throughout the Caribbean and Latin America

D. Masys, P. Cahn, V. Fink, 2010, PloS one.

Dosing Efavirenz in Patients with HIV/TB Coinfection

M. Schechter, 2013 .

Monotherapy with lopinavir/ritonavir

M. Schechter, E. Nunes, 2007, Expert opinion on investigational drugs.

Urinary tract infection in men with AIDS.

M. Schechter, M. Halpern, G. S. Lopes, 1994, Genitourinary medicine.

Zymodeme and species specificities of monoclonal antibodies raised against Trypanosoma cruzi.

M. Chapman, M. Miles, M. Schechter, 1984, Transactions of the Royal Society of Tropical Medicine and Hygiene.

PURIFIED TRYPANOSOMA CRUZI SPECIFIC GLYCOPROTEIN FOR DISCRIMINATIVE SEROLOGICAL DIAGNOSIS OF SOUTH AMERICAN TRYPANOSOMIASIS (CHAGAS' DISEASE)

M. Miles, M. Schechter, F. Guhl, 1983, The Lancet.

Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission

M. Dybul, S. Lewin, D. Havlir, 2018, The Lancet.

Horizontal and vertical transmission of human immunodeficiency virus type 1 dual infections caused by viruses of subtypes B and C.

C. Luo, D. Pieniążek, V. Soriano, 1998, The Journal of infectious diseases.

Dual and recombinant infections: an integral part of the HIV-1 epidemic in Brazil.

D. Pieniążek, A. Tanuri, M. Schechter, 1999, Emerging infectious diseases.

HIV-1 DNA predicts disease progression and post-treatment virological control

M. Carrington, R. Phillips, D. Cooper, 2014, eLife.

Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy

P. Kaleebu, R. Phillips, D. Cooper, 2013, PloS one.

HIV viral load and CD4+ lymphocyte counts in subjects coinfected with HTLV-I and HIV-1.

L. Moulton, L. Harrison, M. Schechter, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Short-course antiretroviral therapy in primary HIV infection.

Steve Kaye, Kholoud Porter, Helen Rees, 2013, The New England journal of medicine.

Overcoming resistance to existing therapies in HIV‐infected patients: The role of new antiretroviral drugs

Jose Gatell, Mauro Schechter, J. Gatell, 2008, Journal of medical virology.

Immunological biomarkers predict HIV-1 viral rebound after treatment interruption

R. Phillips, D. Cooper, C. Willberg, 2015, Nature Communications.

The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels

J. Miro, D. Cooper, J. Weber, 2015, AIDS.

Human T cell lymphotropic virus type II and human immunodeficiency virus type 1 disease progression.

L. Harrison, M. Schechter, 1997, The Journal of infectious diseases.

Human T cell lymphotropic virus type I does not increase human immunodeficiency virus viral load in vivo.

T. Quinn, L. Harrison, M. Schechter, 1997, The Journal of infectious diseases.

Treatment at scale in Brazil: a physician's perspective

M. Schechter, 2007, AIDS.

Mortality after failure of antiretroviral therapy in sub‐Saharan Africa

M. Egger, F. Dabis, P. Braitstein, 2010, Tropical medicine & international health : TM & IH.

Predictors of Virologic Failure in HIV-1-Infected Patients Starting Highly Active Antiretroviral Therapy in Porto Alegre, Brazil

L. Harrison, R. Albernaz, M. Schechter, 2005, Journal of acquired immune deficiency syndromes.

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)

W. Blattner, D. Montefiori, S. Kalams, 2011, PloS one.

HIV Treatment Adherence, Patient Health Literacy, and Health Care Provider–Patient Communication

J. Nachega, J. Rockstroh, J. Zuniga, 2012, Journal of the International Association of Physicians in AIDS Care.

The DART trial: 'The doctor's dilemma' revisited.

M. Schechter, B. Grinsztejn, E. Nunes, 2011, The Journal of antimicrobial chemotherapy.

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

R. Haubrich, C. Katlama, A. Lazzarin, 2009, AIDS.

Tuberculosis in HIV programmes in lower-income countries: practices and risk factors.

M. Egger, F. Dabis, P. Braitstein, 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Monotherapy with Lopinavir/Ritonavir as Maintenance After HIV-1 Viral Suppression: Results of a 96-Week Randomized, Controlled, Open-Label, Pilot Trial (KalMo Study)

M. Schechter, J. C. Faulhaber, J. Pilotto, 2009, HIV clinical trials.

Coinfection with HTLV-I and HIV: increase in HTLV-I-related outcomes but not accelerated HIV disease progression?

L. Harrison, M. Schechter, Mauro Schechter, 1998, AIDS patient care and STDs.

p24 antigenaemia in HIV-1 infected Brazilians correlates with other markers of disease progression.

M. Schechter, C. Hofer, R. Zajdenverg, 1994, The Journal of infection.

Patterns and Correlates of PrEP Drug Detection Among MSM and Transgender Women in the Global iPrEx Study

Megha L Mehrotra, D. Glidden, S. Buchbinder, 2014, Journal of acquired immune deficiency syndromes.

Trypanosoma cruzi: characterization and isolation of a 57/51,000 m.w. surface glycoprotein (GP57/51) expressed by epimastigotes and bloodstream trypomastigotes.

J. Scharfstein, M. Miles, M. Schechter, 1986, Journal of immunology.

Variations induced by different methodologies in Trypanosoma cruzi surface antigen profiles.

M. Schechter, N. Nogueira, 1988, Molecular and biochemical parasitology.

Proposed World-Health-Organization Staging System for Hiv-Infection and Disease - Preliminary Testing by An International Collaborative Cross-Sectional Study

J. Mills, R. Redfield, M. Maj, 1992 .

Protease inhibitors as initial therapy for individuals with an intermediate risk of HIV disease progression: is more necessarily better?

C. Struchiner, L. Harrison, M. Schechter, 1999, AIDS.

Assessment of the role of Staphylococcus epidermidis as a cause of otitis media.

M. Schechter, R. Feigin, P. Shackelford, 1973, Pediatrics.

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries.

L. Myer, A. Mocroft, M. Egger, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Cross-Clade Reactivity of HIV-1-Specific T-cell Responses in HIV-1-Infected Individuals From Botswana and Cameroon

D. Burke, N. Wolfe, J. Shiver, 2006, Journal of acquired immune deficiency syndromes.

Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis

Mauro Schechter, Amilcar Tanuri, N. Torre, 2004, Virus Genes.

Further evaluation of lectin affinity purified glycoprotein (GP90) in the enzyme linked immunosorbent assay (ELISA) for diagnosis of Trypanosoma cruzi infection.

M. Miles, M. Schechter, A. Rassi, 1985, Transactions of the Royal Society of Tropical Medicine and Hygiene.

HTLV-I-associated neurologic manifestations in four generations of a Brazilian family.

M. Schechter, O. F. Ferreira Júnior, M. Puccioni, 1993, Journal of acquired immune deficiency syndromes.

The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study

D. Glidden, R. Grant, P. Defechereux, 2016, AIDS and Behavior.

Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.

D. Glidden, S. Buchbinder, R. Grant, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine

D. Glidden, S. Buchbinder, R. Grant, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.

J. Lundgren, J. Neaton, B. Grund, 2018, The lancet. HIV.

Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.

D. Glidden, L. Benet, S. Buchbinder, 2016, The lancet. HIV.

The Development of PROQOL-HIV: An International Instrument to Assess the Health-Related Quality of Life of Persons Living With HIV/AIDS

Baiba Berzins, Mauro Schechter, Olivier Chassany, 2012, Journal of acquired immune deficiency syndromes.

Mortality During the First Year of Potent Antiretroviral Therapy in HIV-1-Infected Patients in 7 Sites Throughout Latin America and the Caribbean

D. Masys, P. Cahn, J. Pape, 2009, Journal of acquired immune deficiency syndromes.

Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis

D. Glidden, S. Buchbinder, R. Grant, 2017, Journal of acquired immune deficiency syndromes.

Barriers to recruit female commercial sex workers for HIV vaccine trials: the Rio de Janeiro experience.

J. Pedrosa, M. Schechter, J. C. Faulhaber, 2009, Journal of acquired immune deficiency syndromes.

Adherence to Antiretroviral Therapy and Persistence of HIV RNA in Semen

Phalguni Gupta, L. Harrison, M. Schechter, 2003, Journal of acquired immune deficiency syndromes.

Modeling the Slow CD4+ T Cell Decline in HIV-Infected Individuals

Libin Rong, Sunpeng Wang, Patricia Hottz, 2015, PLoS Comput. Biol..

Anderson Efficacy in Men Who Have Sex with Men Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis

D. Glidden, S. Buchbinder, R. Grant, 2012 .

International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status.

S. Buchbinder, R. Grant, L. Bekker, 2017, Sexually transmitted diseases.

Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.

D. Glidden, S. Buchbinder, R. Grant, 2019, AIDS research and human retroviruses.

Therapy for early HIV infection: how far back should the pendulum swing?

M. Schechter, 2004, The Journal of infectious diseases.

Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy.

L. Harrison, M. Schechter, G. Santoro-Lopes, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Epidemiologic investigation of Reye syndrome.

M. Haymond, M. Schechter, R. Feigin, 1975, The Journal of pediatrics.

Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort

P. Kaleebu, D. Cooper, J. Weber, 2021, AIDS (London, England).

Discordant Responses to Potent Antiretroviral Treatment in Previously Naive HIV-1-Infected Adults Initiating Treatment in Resource-Constrained Countries: The Antiretroviral Therapy in Low-Income Countries (ART-LINC) Collaboration

R. Stone, M. Egger, F. Dabis, 2007, Journal of acquired immune deficiency syndromes.

Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection.

J. Gatell, M. Schechter, C. Perno, 2008, AIDS patient care and STDs.

Ending AIDS as a Public Health Threat by 2030: Scientific Developments from the 2016 Interest Conference in Yaoundé, Cameroon

C. Boucher, G. Ferrari, E. Katabira, 2017, Antiviral therapy.

Mpox in people with advanced HIV infection: a global case series

B. Clotet, P. Cahn, J. Blanco, 2023, The Lancet.

CD4+ blood lymphocytes are rapidly killed in vitro by contact with autologous human immunodeficiency virus-infected cells.

M. Schechter, F. Valentine, B. Nardelli, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Human T Lymphotropic Virus Type I and II Infections in Healthy Blood Donors from Rio de Janeiro, Brazil

M. Schechter, Orlando C. Ferreira, M. Cavalcanti, 1996, Vox sanguinis.

HIV disease progression and V3 serotypes in Brazil: is B different from B-Br?

L. Harrison, M. Schechter, G. Santoro-Lopes, 2000, AIDS research and human retroviruses.

Streamlining HIV Testing for HIV Preexposure Prophylaxis

D. Glidden, R. Grant, M. Schechter, 2014, Journal of Clinical Microbiology.

Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy.

M. Schechter, P. Barroso, M. V. Vettore, 2006, The Journal of infection.

CD 4 + blood lymphocytes are rapidly killed in vitro by contact with autologous human immunodeficiency virus-infected cells

M. Schechter, Charles J. Gonzalez, B. Nardelli, 2022 .

Reactivity to purified protein derivative and the risk of tuberculosis in HIV-infected Brazilian patients.

M. Schechter, R. Zajdenverg, A. A. Baptista, 1993, Chest.

Plasma HIV Viral Rebound following Protocol-Indicated Cessation of ART Commenced in Primary and Chronic HIV Infection

D. Cooper, J. Weber, M. Schechter, 2012, PloS one.

Effectiveness of Antiretroviral Therapy Among Patients Who Attend Public HIV Clinics in Rio de Janeiro, Brazil

L. Harrison, M. Schechter, C. Hofer, 2004, Journal of acquired immune deficiency syndromes.

Effectiveness of highly active antiretroviral therapy using non-brand name drugs in Brazil.

M. Schechter, J. C. Faulhaber, P. Barroso, 2007, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

neutralizing antibodies : Correlates of high d 5 titers and implications for potential HIV vaccine trials

M. Schechter, S. Guptaa, Christopher Masta, 2009 .

Mortality of HIV-infected patients in low-income countries – Authors’ response

F. Dabis, M. Egger, M. Schechter, 2006, The Lancet.

Temporal Changes in Causes of Death Among HIV-Infected Patients in the HAART Era in Rio de Janeiro, Brazil

L. Harrison, A. Pacheco, M. Schechter, 2009, Journal of acquired immune deficiency syndromes.

Track C Epidemiology and Prevention Science

David R. Holtgrave, W. Heneine, Y. Nakamura, 2012, Journal of the International AIDS Society.

Viral Load and CD4 Count Dynamics After HIV-1 Seroconversion in Homosexual and Bisexual Men in Rio de Janeiro, Brazil

C. Struchiner, A. Pacheco, M. Schechter, 2006, Journal of acquired immune deficiency syndromes.

Lessons From a Multisite International Trial in the Caribbean and South America of an HIV-1 Canarypox Vaccine (ALVAC-HIV vCP1452) With or Without Boosting With MN rgp120

D. Montefiori, S. Gurunathan, D. Lawrence, 2007, Journal of acquired immune deficiency syndromes.

Identification of a high-risk heterosexual population for HIV prevention trials in Rio de Janeiro, Brazil. Projeto Praço Onze Study Group.

H. Sheppard, L. Harrison, M. Schechter, 2000, Journal of acquired immune deficiency syndromes.

Identification of a high-risk heterosexual population for HIV prevention trials in Rio de Janeiro, Brazil.

H. Sheppard, L. Harrison, M. Schechter, 2000 .

Brief Report: Identification of a High‐Risk Heterosexual Population for HIV Prevention Trials in Rio de Janeiro, Brazil

H. Sheppard, L. Harrison, M. Schechter, 2000 .

Egocentric network data provide additional information for characterizing an individual's HIV risk profile

P. Langenberg, L. Hungerford, M. Schechter, 2010, AIDS.

Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection.

R. Paredes, H. Furrer, A. Phillips, 2023, NEJM evidence.

Psychometric validation of PROQOL-HIV: A contemporaneous and cross-cultural Health-Related Quality-of-Life (HRQL) Questionnaire specific to HIV

O. Chassany, C. Acquadro, M. Duracinsky, 2009 .

Even at High CD4-Cell Counts, Mortality Rates Are High in Untreated HIV Infection

M. Schechter, 2012 .

Oral Tenofovir Disoproxil Fumarate and Its Impact in Herpes Simplex Virus Type-2 Acquisition and Clinical Expression

R. Grant, S. Shiboski, K. Mayer, 2011 .

Acute retrovirus syndrome among prospectively identified homosexual men with incident HIV infection in Brazil. Projecto Praça Onze Study Group.

C. Struchiner, L. Harrison, M. Schechter, 2000 .

HIV vaccine evaluation center in Rio de Janeiro, Brazil.

M. Schechter, 2002, Vaccine.

Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort

P. Kaleebu, D. Cooper, J. Weber, 2021, AIDS (London).

Willingness to Participate in HIV Vaccine Trials Among Men Who Have Sex With Men in Rio de Janeiro, Brazil

L. Harrison, M. Schechter, A. Périssé, 2000, Journal of acquired immune deficiency syndromes.

Effectiveness of Antiretroviral Therapy Among Patients Who Attend Public HIV Clinics in Rio de Janeiro, Brazil

L. Harrison, M. Schechter, C. Hofer, 2004 .

Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil

M. Schechter, R. Diaz, J. Galinskas, 2023, BMC Infectious Diseases.

J. Nachega, J. Rockstroh, C. Beyrer, 2012, Journal of the International Association of Physicians in AIDS Care.

Sequence and phylogenetic analysis of glycoprotein 120 of an HIV type 1 variant (GWGR) prevalent in Brazil.

A. Tanuri, A. Vicente, M. Schechter, 1995, AIDS research and human retroviruses.

Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.

D. Glidden, S. Buchbinder, R. Grant, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Temporal Changes in Causes of Death Among HIV-Infected Patients in the HAART Era in Rio de Janeiro, Brazil

L. Harrison, A. Pacheco, M. Schechter, 2009, Journal of acquired immune deficiency syndromes.

Validation of a Hierarchical Deterministic Record-Linkage Algorithm Using Data From 2 Different Cohorts of Human Immunodeficiency Virus-Infected Persons and Mortality Databases in Brazil

R. Chaisson, L. Moulton, L. Harrison, 2008, American journal of epidemiology.

Molecular and epidemiologic evidence for the discontinuous introduction of subtypes B and F into Rio de Janeiro, Brazil.

A. Tanuri, M. Schechter, M. E. Pinto, 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Estimating the extent of underreporting of mortality among HIV-infected individuals in Rio de Janeiro, Brazil.

R. Chaisson, L. Moulton, L. Harrison, 2011, AIDS research and human retroviruses.

CHAPTER 61 – Universal Access to Antiretroviral Therapy: The Brazilian Experience

M. Schechter, M. Charles, 2008 .